Understanding how a specific cytokine affects immune responses in colorectal cancer spread
Cytokine-mediated regulation of immunity and microenvironment in colorectal cancer metastasis
This study is looking at how a substance called Interleukin 27 (IL27) affects the environment around colorectal cancer tumors and how it might influence the spread of cancer, with the hope of finding new ways to improve treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11009541 on NIH RePORTER |
What this research studies
This research investigates the role of Interleukin 27 (IL27) in the tumor microenvironment of colorectal cancer (CRC) and its impact on cancer metastasis. By examining how IL27 influences immune responses, the study aims to uncover mechanisms that could lead to improved immunotherapies for CRC. The researchers will utilize advanced models and techniques, including genetic modifications and molecular biology methods, to explore the relationship between IL27 levels and tumor progression. Patients may benefit from insights that could lead to new treatment strategies targeting IL27.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced colorectal cancer, particularly those with metastatic disease.
Not a fit: Patients with early-stage colorectal cancer or those not diagnosed with colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for colorectal cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting cytokines for cancer treatment, suggesting potential success for this approach.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Grivennikov, Sergei I — Cedars-Sinai Medical Center
- Study coordinator: Grivennikov, Sergei I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.